VSTM (Verastem) Institutional Ownership : 70.07% (As of Dec. 13, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Verastem Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Verastem's institutional ownership is 70.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Verastem's Insider Ownership is 5.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Verastem's Float Percentage Of Total Shares Outstanding is 99.67%.

Verastem Institutional Ownership Historical Data

The historical data trend for Verastem's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Institutional Ownership Chart

Verastem Historical Data

The historical data trend for Verastem can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	8.93	8.69	8.68	8.83	15.42	13.40	13.61	18.39	18.41	16.82

Verastem Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Verastem Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

0LOV:UK 2VSA:Germany

Address

117 Kendrick Street, Suite 500, Needham, MA, USA, 02494

Website

https://www.verastem.com

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Executives

Dan Paterson	officer: Chief Operating Officer	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Daniel Calkins	officer: Vice President of Finance	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik	director	C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Robert E. Gagnon	officer: Chief Financial Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Karin Anna Tollefson	director	C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur	director	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104